Markers for bone metabolism in a long-lived case of thanatophoric dysplasia

Endocrine Journal

Volumn 47, Issue SUPPL., 2000, Pages

  Kuno, Tateo ^a   Fujita, Ichiro ^a   Miyazaki, Sumio ^a   Katsumata, Noriyuki ^b  

^a SAGA UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Acanthosis nigricance; Development; Fibroblast growth factor receptor 3; Growth

Indexed keywords

ACANTHOSIS NIGRICANS; ARTICLE; BONE METABOLISM; CASE REPORT; HUMAN; MALE; RESPIRATORY FAILURE; SCHOOL CHILD; THANATOPHORIC DWARFISM; UROLITHIASIS;

EID: 0034052393     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.47.supplmarch_s141     Document Type: Article

References (6)

1. Katsumata N, Kuno T, Miyazaki S, Mikami S, Nagashima-Miyokawa A, Nimura A, Horikawa R, Tanaka T (1998) G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia. Endocrine J 45: S171-S174.
2. Kikuchi T, Hashimoto N, Kawasaki T, Kataoka S, Takahashi H, Uchiyama M (1998) Plasma levels of carboxy terminal propeptide of type I procollagen and pyridinoline cross-linked telopeptide of type I collagen in healthy school children. Acta Paediatr 87: 825-829.
3. Kuno T, Tasaki H, Miyazaki S, Horie H (1997) Rapid decrease of urinary pyridinoline excretion in growth hormone deficient children following discontinuation of growth hormone therapy. Acta Pediatr Jpn 39: 18-20.
4. Kuno T, Miyazaki S (1998) Changes in levels of serum and urinary collagen-related substances in growth hormone deficient children following discontinuation of growth hormone therapy. Endocrine J 45: S151-S153.
5. MacDonald IM, Hunter AGW, MacLeod PM, MacMurray SB (1989) Growth and development in thanatophoric dysplasia. Am J Med Genet 33: 508-512.
6. Baker KM, Olson DS, Harding CO, Pauli RM (1997) Long-term survival in typical thanatophoric dysplasia type 1. Am J Med Genet 70: 427-436.